209 related articles for article (PubMed ID: 21799048)
1. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach.
Huang Z; Lin L; Gao Y; Chen Y; Yan X; Xing J; Hang W
Mol Cell Proteomics; 2011 Oct; 10(10):M111.007922. PubMed ID: 21799048
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
3. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
7. Untargeted saliva metabonomics study of breast cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations.
Zhong L; Cheng F; Lu X; Duan Y; Wang X
Talanta; 2016 Sep; 158():351-360. PubMed ID: 27343615
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
[TBL] [Abstract][Full Text] [Related]
9. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
10. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach.
Bansal N; Gupta A; Mitash N; Shakya PS; Mandhani A; Mahdi AA; Sankhwar SN; Mandal SK
J Proteome Res; 2013 Dec; 12(12):5839-50. PubMed ID: 24219689
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
Łuczykowski K; Warmuzińska N; Operacz S; Stryjak I; Bogusiewicz J; Jacyna J; Wawrzyniak R; Struck-Lewicka W; Markuszewski MJ; Bojko B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920347
[TBL] [Abstract][Full Text] [Related]
12. Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery.
Zhang T; Watson DG; Wang L; Abbas M; Murdoch L; Bashford L; Ahmad I; Lam NY; Ng AC; Leung HY
PLoS One; 2013; 8(6):e65880. PubMed ID: 23823321
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
14. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
15. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
Lin L; Huang Z; Gao Y; Chen Y; Hang W; Xing J; Yan X
Proteomics; 2012 Aug; 12(14):2238-46. PubMed ID: 22685041
[TBL] [Abstract][Full Text] [Related]
16. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
17. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
[TBL] [Abstract][Full Text] [Related]
18. Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers.
Chen YT; Huang HC; Hsieh YJ; Fu SH; Li L; Chen CL; Chu LJ; Yu JS
J Food Drug Anal; 2019 Apr; 27(2):460-474. PubMed ID: 30987717
[TBL] [Abstract][Full Text] [Related]
19. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
20. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]